News from imaginab, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 11, 2016, 08:00 ET

ImaginAb Appoints Benjamin Chen, Ph.D., as CEO, Joseph Limber as Chairman, and Forms Medical Advisory Board

 ImaginAb Inc. today announced the appointment of Benjamin Chen, Ph.D., as chief executive officer and Joseph Limber as chairman of the board...

Jan 06, 2016, 08:00 ET

ImaginAb's PSMA Imaging Agent Detects More Lesions Compared to Standard Imaging Methods for Detection of Prostate Cancer in Phase I/IIa Study

ImaginAb Inc. today announced clinical results from a Phase I/IIa trial of IAB2M, ImaginAb's proprietary precision imaging agent for the detection...

Nov 03, 2015, 08:00 ET

ImaginAb Presents Precision Immuno-imaging Data at Society for Immunotherapy of Cancer (SITC) 2015 Annual Meeting

 ImaginAb Inc. today announced results from a preclinical trial of IAB22M2C, the company's proprietary CD8 T-cell imaging agent, demonstrating...

Sep 23, 2015, 08:00 ET

ImaginAb Appoints Jeff Bailey to Board of Directors

 ImaginAb Inc., a clinical-stage immune imaging company, today announced the appointment of Jeff Bailey to its board of directors. Mr. Bailey...

Sep 09, 2015, 09:00 ET

ImaginAb to Present at Rodman & Renshaw 17th Annual Global Investment Conference

 ImaginAb Inc., a clinical-stage immune imaging company, announced today that Roger Crystal, M.D., chief business officer for ImaginAb, will...

Sep 08, 2015, 09:00 ET

Study Presented at 2015 World Molecular Imaging Conference Shows ImaginAb's Precision Imaging of Prostate Cancer Outperforms Conventional Imaging

 ImaginAb Inc. has released interim results from a Phase 2 clinical trial of IAB2M, the company's proprietary imaging agent for management of...

Jun 05, 2015, 18:08 ET
www.imaginab.com

ImaginAb's Prostate Imaging Phase I/IIa data will be presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, alongside pre-clinical CD3+ T-cell imaging data

 Memorial Sloan-Kettering Cancer Center (MKSCC), will be presenting ImaginAb's Phase I/IIa clinical imaging data with IAB2M in patients with...

Sep 17, 2014, 09:07 ET

ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging

 ImaginAb, Inc. today announced that it has entered into an exclusive technology development partnership with Novotectid GmbH for the...

Jul 28, 2014, 08:00 ET

ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development

 ImaginAb, Inc. today announced today announced that it has appointed Roger Crystal, MD as Vice President of Business Development. Dr. Crystal...

Jun 10, 2014, 16:00 ET

NCM and ImaginAb Ink Clinical Isotope Supply and Labeling Agreement

NCM USA announced today it has signed a long-term clinical zirconium isotope (89Zr) supply and cGMP biologics labeling agreement with ImaginAb,...

Jun 09, 2014, 08:00 ET

ImaginAb Partners with IBA Molecular for Clinical Supply of 89Zr Labeled Drug Product

 ImaginAb, Inc. (ImaginAb) and IBA Molecular North America, Inc. (IBA Molecular) announced that IBA Molecular has been selected to...

Jun 06, 2014, 08:00 ET

ImaginAb Presents Initial Phase I/IIa Results for Prostate Imaging Agent at Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

 ImaginAb, Inc., in collaboration with Memorial Sloan-Kettering Cancer Center (MKSCC), will be presenting initial clinical data with an...

Jun 03, 2014, 09:56 ET

ImaginAb Enters into Exclusive Licensing Agreement with UCLA for Immune Cell Imaging Agents

 ImaginAb, Inc. and the Regents of the University of California, Los Angeles (UCLA) have executed a technology licensing agreement relating to...

May 21, 2014, 11:22 ET

ImaginAb Launches Japanese Subsidiary

ImaginAb, Inc. announced today the formal launch of ImaginAb Japan KK, a wholly-owned subsidiary of Los Angeles-based ImaginAb, Inc....

May 08, 2014, 14:50 ET

ImaginAb Concludes $21 Million Series B Financing

 ImaginAb, Inc., a clinical stage biotechnology company that engineers antibodies into smaller protein formats optimized for in vivo molecular...

Feb 10, 2014, 09:00 ET

ImaginAb and Duke-NUS Launch Imaging Biomarker Development Lab (IBDL)

 ImaginAb, Inc. today announced that it has entered into a partnership with the Duke-NUS Graduate Medical School Singapore...

Nov 25, 2013, 14:15 ET

ImaginAb Expands Scientific Advisory Board

ImaginAb, Inc., a clinical-stage company developing in vivo molecular imaging agents based on antibody fragment technology, today announced that it...

Apr 01, 2013, 08:30 ET

Emerging Precision Medicine Powerhouse Changes Name to Increase Visibility and Overall Awesomeness

ImaginAb, Inc., a clinical-stage company developing in vivo molecular imaging agents based on antibody technology, today announced that it has...

Oct 08, 2012, 08:00 ET

ImaginAb and Lundbeck to Collaborate in Neurodegeneration

ImaginAb, Inc., a clinical-stage company developing in vivo molecular imaging agents based on antibody fragment technology, today announced that it...

Sep 05, 2012, 07:30 ET

ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer

 ImaginAb, Inc. a developer of in vivo molecular imaging agents based on its proprietary antibody fragment platform, today announced that it...